

Date: January 23, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Submission of Media Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Consolidated and Standalone Un-audited financial results of the company for the quarter and nine months ended December 31, 2024 duly approved by the Board of Directors of the Company in their meeting held on January 23, 2025.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India


P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED


Stellar Financial & Operational Performance for Q3 & 9MFY25

Ahmedabad, Gujarat, 23rd January 2025 – Senores Pharmaceuticals Limited a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its Unaudited Financial Results for the 3rd Quarter of FY25 ended 31st December 2024


Q3 & 9MFY25 CONSOLIDATED FINANCIAL HIGHLIGHTS




Income (INR Crs)




EBITDA* (INR Crs)




PAT after MI (INR Crs)



EBITDA Margin (%)



PAT Margin after MI (%)




* EBITDA includes Other Operating Income but excludes non-operating income.

Q3 & 9MFY25 OPERATIONAL & FINANCIAL HIGHLIGHTS


Revenue Breakup

Regulated Markets Emerging Markets Others


Q3FY24




Q3FY25




9MFY24




9MFY25




Regulated Market



Emerging Market



Others Market



- For 9MFY25, regulated market business revenues stood at Rs. 180.5 crs, a growth of ~100% on a Y-o-Y basis. EBIDTA margins for regulated market business stood at 40% for Q3 & 9MFY25.
- Our Emerging markets business revenues stood at Rs. 84.6 crs, growing by more than 10 times on a Y-o-Y basis. Emerging markets business EBIDTA stood at 0.9% for Q3FY25 and 1.4% for 9MFY25.
- In the regulated markets currently, company has;
 - 22 Owned commercial products
 - 24 Approved ANDA's
 - 51 Pipeline products with 28 CGT opportunity products
 - 21 CDMO/CMO commercial products
 - 69 CDMO/CMO Pipeline products
- For the emerging markets currently, company has;
 - 237 Approved products
 - 537 products under registration
 - Presence across more than 40 countries

Commenting on the results, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

*“We are pleased to report strong performance for Q3 and 9MFY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our revenue and profitability for 9MFY25 have increased by **over 150%** year-on-year, and we are optimistic about sustaining this momentum going forward.*

*In Regulated Markets, robust growth in the CDMO/CMO segment was partly offset by a softer performance in the Marketed Products segment, which was impacted by the high base of Q3FY24. The consolidation of acquired businesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. Year-on-year, the Regulated Markets and Emerging Markets **businesses grew by approximately 100% and over 10 times**, respectively, for 9MFY25.*

*In 9MFY25, we launched one new product and received ANDA approval for five products in the Regulated Markets business, bringing our **total ANDA approvals to 24**.*

*Our Emerging Markets business is growing well through portfolio and footprint expansion. Our registered product portfolio in the Emerging Markets business **expanded to 267 products**. With a strong product portfolio, we are now realigning our go-to-market models to make our Emerging Markets operations more profitable.*

*We are seeing significant traction and scale-up in our CDMO/CMO segment. Currently, we **manufacture 21 products** in this business and expect faster growth with the addition of new products, customers, and increased wallet share from existing customers.*

We remain focused on executing our business strategies across segments and are confident that healthy growth will continue in the year ahead.”

About Senores Pharmaceuticals Company Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 24 ANDA and 21 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 260 product registrations and 530 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: U24290GJ2017PLC100263

Mr. Deval Shah

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899